Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1979 Oct;67(2):309–318. doi: 10.1111/j.1476-5381.1979.tb08681.x

The influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain-amine depleting neuroleptics or by cholinomimetics

Luis D Fuenmayor, Marthe Vogt
PMCID: PMC2043889  PMID: 40649

Abstract

1 Catalepsy was produced in rats and mice by the subcutaneous injection of either tetrabenazine or the butyrophenone U-32,802A (4′-fluoro-4-{[4-(p-fluorophenyl)-3-cyclohexen-1-yl]amino} butyrophenone hydrochloride). Catalepsy was evaluated by the duration of total immobility on a vertical grid.

2 Pretreatment with p-chlorophenylalanine (PCPA) reduced the intensity of catalepsy by 50% or more, whereas its time course remained the same.

3 5-Hydroxytryptophan (5-HTP), 10 mg/kg, enhanced the catalepsy induced by U-32,802A or tetrabenazine, provided it was administered soon (45 min) after the neuroleptic; injections at 90 min had no effect. Otherwise untreated rats given this dose of 5-HTP behaved normally on the grid.

4 The anticataleptic effect of PCPA was reversed by 5-HTP.

5 Measurable changes in 5-hydroxytryptamine (5-HT) metabolism in the rat forebrain accompanied the modification of catalepsy by 5-HTP and PCPA.

6 Methysergide (5 mg/kg) given 30 min before the neuroleptics to either mice or rats reduced the catalepsy, assessed 2.5 h after the methysergide. It also prevented the increase in neuroleptic-induced catalepsy following 5-HTP, 10 mg/kg.

7 Tryptophan, like 5-HTP, increased the catalepsy seen in mice after U-32,802A and tetrabenazine, and increased the production of 5-hydroxyindol-3-ylacetic acid in the forebrain.

8 In the rat, intracerebroventricular injection of physostigmine produced catalepsy which was not modified by methysergide or PCPA but was abolished by atropine. Similarly, in the mouse, catalepsy induced by the subcutaneous injection of pilocarpine was abolished by atropine but not affected by either methysergide or 5-HTP.

9 Atropine greatly reduced the catalepsy induced by U-32,802A and tetrabenazine but lowered striatal homovanillic acid (HVA) only after U-32,802A. D,L-DOPA, 20 mg/kg, diminished the cataleptogenic effect of both neuroleptics and raised striatal HVA.

10 The results support the view that there is a facilitating or permissive action of 5-HT-containing neurones on neuroleptic-induced catalepsy.

Full text

PDF
309

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahtee L. Effect of cholingeric drugs on methadone-induced catalepsy and stereotypies in rats treated chronically with methadone. Eur J Pharmacol. 1976 Oct;39(2):203–213. doi: 10.1016/0014-2999(76)90128-x. [DOI] [PubMed] [Google Scholar]
  2. Baldessarini R. J., Amatruda T. T., 3rd, Griffith F. F., Gerson S. Differential effects of serotonin on turning and sterotypy induced by apomorphine. Brain Res. 1975 Jul 25;93(1):158–163. doi: 10.1016/0006-8993(75)90295-4. [DOI] [PubMed] [Google Scholar]
  3. Carter C. J., Pycock C. J. A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn Schmiedebergs Arch Pharmacol. 1978 Sep;304(2):135–139. doi: 10.1007/BF00495549. [DOI] [PubMed] [Google Scholar]
  4. Cerbo R., Carchedi F., Casacchia M. Ruolo della serotonina nella catatonia da aloperidolo e da reserpina. Boll Soc Ital Biol Sper. 1976 Feb 28;52(4):245–250. [PubMed] [Google Scholar]
  5. Costall B., Fortune D. H., Naylor R. J., Mardsen C. D., Pycock C. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology. 1975 Nov;14(11):859–868. doi: 10.1016/0028-3908(75)90114-8. [DOI] [PubMed] [Google Scholar]
  6. Costall B., Olley J. E. Cholinergic- and neuroleptic-induced catalepsy: modification by lesions in the caudate-putamen. Neuropharmacology. 1971 May;10(3):297–306. doi: 10.1016/0028-3908(71)90053-0. [DOI] [PubMed] [Google Scholar]
  7. FELDBERG W., SHERWOOD S. L. Behaviour of cats after intraventricular injections of eserine and DFP. J Physiol. 1954 Sep 28;125(3):488–500. doi: 10.1113/jphysiol.1954.sp005175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gumulka W., Kostowski W., Czlonkowski A. Role of 5-HT in the action of some drugs affecting extrapyramidal system. Pharmacology. 1973;10(6):363–372. doi: 10.1159/000136458. [DOI] [PubMed] [Google Scholar]
  9. Hornykiewicz O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br Med Bull. 1973 May;29(2):172–178. doi: 10.1093/oxfordjournals.bmb.a070990. [DOI] [PubMed] [Google Scholar]
  10. Kostowski W., Gumulka W., Cxlonkowski A. Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res. 1972 Dec 24;48:443–446. doi: 10.1016/0006-8993(72)90208-9. [DOI] [PubMed] [Google Scholar]
  11. Lahti R. A., Lednicer D. Effect of a butyrophenone derivative, U-32,802A, on brain biogenic amines. Biochem Pharmacol. 1974 Jun 15;23(12):1701–1705. doi: 10.1016/0006-2952(74)90397-9. [DOI] [PubMed] [Google Scholar]
  12. Maj J., Mogilnicka E., Przewlocka B. Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy. Pharmacol Biochem Behav. 1975 Jan-Feb;3(1):25–27. doi: 10.1016/0091-3057(75)90076-3. [DOI] [PubMed] [Google Scholar]
  13. Maj J., Sowińska H., Baran L. Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy. Arch Immunol Ther Exp (Warsz) 1976;24(2):197–203. [PubMed] [Google Scholar]
  14. Milson J. A., Pycock C. J. Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice. Br J Pharmacol. 1976 Jan;56(1):77–85. doi: 10.1111/j.1476-5381.1976.tb06961.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. O'Keeffe R., Sharman D. F., Vogt M. Effect of drugs used in psychoses on cerebral dopamine metabolism. Br J Pharmacol. 1970 Feb;38(2):287–304. doi: 10.1111/j.1476-5381.1970.tb08517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Papeschi R., Randrup A. Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors. Pharmakopsychiatr Neuropsychopharmakol. 1973 May;6(3):137–157. doi: 10.1055/s-0028-1094377. [DOI] [PubMed] [Google Scholar]
  17. Tachiki K. H., Takagi A., Tateishi T., Kido A., Nishiwaki K., Nakamura E., Nagayama H., Takahashi R. Animal model of depression. III. Mechanism of action of tetrabenazine. Biol Psychiatry. 1978 Aug;13(4):429–443. [PubMed] [Google Scholar]
  18. Timsit J. Sur l'activité cataleptigène DE QUELQUES D'ERIV'ES DE LA BUTYROPH'ENONE. Therapie. 1966 Nov-Dec;21(6):1453–1471. [PubMed] [Google Scholar]
  19. Zetler G. Cataleptic state and hypothermia in mice, caused by central cholinergic stimulation and antagonized by anticholinergic and antidepressant drugs. Int J Neuropharmacol. 1968 Jul;7(4):325–335. doi: 10.1016/0028-3908(68)90015-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES